Boston Scientific Corporation

1590 articles with Boston Scientific Corporation

• Boston Scientific Announces Conference Call Discussing Second Quarter 2022 Results

  6/29/2022

  Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2022 on Wednesday, July 27, 2022 at 8:00 a.m. EDT.

• Boston Scientific Announces Agreement to Purchase Majority Stake of M.I.Tech Co., Ltd from Synergy Innovation Co., Ltd

  6/15/2022

  Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Synergy Innovation Co., Ltd, to purchase its majority stake (approximately 64 percent) of M.I.Tech Co., Ltd, ("M.I.Tech").

• Boston Scientific to Participate in Bank of America Global Healthcare Conference

  5/2/2022

  Boston Scientific Corporation will participate in Bank of America's Global Healthcare Conference on Thursday, May 12.

• Boston Scientific Announces Results For First Quarter 2022

  4/27/2022

  Boston Scientific Corporation generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational1 basis and 9.7 percent on an organic2 basis, all compared to the prior year period.

• Boston Scientific Announces Conference Call Discussing First Quarter 2022 Results

  4/1/2022

  Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2022, on Wednesday, April 27, 2022 , at 8:00 a.m. EDT.

• Boston Scientific Announces Early Results of Its Cash Tender Offer for Its Outstanding Debt Securities and Increases Aggregate Maximum Principal Amount of Its Cash Tender Offer

  3/16/2022

  Boston Scientific Corporation announced that, pursuant to the previously announced cash tender offer for up to $2.5 billion aggregate principal amount of the outstanding senior notes identified in the table and the related notes below, $5,139,194,000 in aggregate principal amount of the Securities were validly tendered and not validly withdrawn on or prior to 5:00 p.m., Eastern Time, on March 15, 2022.

• Boston Scientific Announces Pricing Terms of Its Cash Tender Offer - Mar 16, 2022

  3/16/2022

  Boston Scientific Corporation announced the pricing terms of the previously announced upsized cash tender offer for $2,852,561,000 in aggregate principal amount of the outstanding senior notes identified in the table and the related notes below.

• Boston Scientific Announces Completion of €3.0 Billion Offering of Senior Notes

  3/8/2022

  Boston Scientific Corporation announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has completed a public offering of €1,000,000,000 aggregate principal amount of 0.750% notes due 2025, €750,000,000 aggregate principal amount of 1.375% notes due 2028, €750,000,000 aggregate principal amount of 1.625% notes due 2031 and €500,000,000 aggregate principal amount of 1.875% notes due 2034.

• Boston Scientific Announces Pricing of €3.0 Billion of Senior Notes

  3/4/2022

  Boston Scientific Corporation has priced a public offering of €1,000,000,000 aggregate principal amount of 0.750% notes due 2025.

• Boston Scientific Announces Cash Tender Offer for up to $2.5 Billion of Its Outstanding Debt Securities

  3/2/2022

  Boston Scientific Corporation announced the commencement of a cash tender offer for up to $2.5 billion aggregate principal amount of the outstanding senior notes listed in the table below.

• Late-Breaking Study Results Reinforce Positive Real-World Outcomes with the WATCHMAN FLX™ LAAC Device

  2/28/2022

  Boston Scientific Corporation (NYSE: BSX) today announced positive results from a new analysis assessing real-world outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Presented during a late-breaking trial session at the Cardiovascular Research Technologies (CRT) 2022 meeting.

• Boston Scientific Closes Acquisition of Baylis Medical Company Inc.

  2/15/2022

  Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc.

• Boston Scientific to Participate in 11th Annual SVB Leerink Global Healthcare Conference

  2/14/2022

  Boston Scientific Corporation (NYSE: BSX) will participate in SVB Leerink's 11th Annual Global Healthcare Conference on Thursday, February 17, 2022.

• BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2021

  2/2/2022

  Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.127 billion during the fourth quarter of 2021, growing 15.4 percent on a reported basis, 16.9 percent on an operational 1 basis and 15.1 percent on an organic 2 basis, all compared to the prior year period.

• Boston Scientific to Present New Data on Advances in Chronic Pain Care at the 2022 North American Neuromodulation Society (NANS) Meeting

  1/7/2022

  Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at the 25th North American Neuromodulation Society (NANS) annual meeting, in Orlando, Florida, on Jan.13-15, 2022.

• Boston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2021 Results

  1/4/2022

  Boston Scientific Corporation (NYSE: BSX) will participate in the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022.

• Boston Scientific Initiates Trial to Evaluate Industry's First Modular CRM System

  12/2/2021

  Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™ Modular Therapy System.

• Boston Scientific Announces Upcoming Conference Schedule - Nov 08, 2021

  11/8/2021

  On November 15, 2021, Dan Brennan, executive vice president and chief financial officer, and Lauren Tengler, vice president, Investor Relations, will participate in a 30-minute question-and-answer session with the host analyst at the virtual 2021 Stifel Healthcare Conference.

• Nevro Announces Update in Patent Litigation with Boston Scientific

  11/1/2021

  Nevro Corp., a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, announced that a Delaware jury found that Nevro infringed two Boston Scientific patents directed to ways of manufacturing spinal cord stimulation leads, which Nevro obtains from a third-party supplier.

• Boston Scientific Announces Results For Third Quarter 2021

  10/27/2021

  Boston Scientific Corporation generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported basis, 9.7 percent on an operational1 basis and 10.6 percent on an organic2 basis, all compared to the prior year period.